sglt2 inhibitors vs glp-1 agonists or receptor as second-line therapy in | VHRM GLP-1 Receptor Agonists and SGLT2

Researchers note the limited number of treatment options for alcohol use disorder, and this study could help determine whether brenipatide becomes a new option pending a future FDA decision

Substance use disorders An emerging area of interest for GLP-1RAs is their potential role in the treatment of substance use disorders, including alcohol and nicotine dependence.[51] GLP-1 is endogenously produced in the nucleus tractus solitarius of the brainstem and acts as a neuropeptide modulating reward and addiction pathways.[52, 53] GLP-1 receptors are expressed in key regions involved in reinforcement, including the ventral tegmental area and nucleus accumbens, where they modulate glutamatergic signaling, potentially influencing feeding and substance-related behaviors.[53, 54] Though ongoing trials are actively investigating the role of GLP-1RAs in substance use disorders, the current evidence base is constrained by a small number of studies, limited randomized controlled trials, heterogeneity in agents evaluated, and variability in outcome measures.[55] One cohort study of U.S

Nausea, vomiting, diarrhea, and constipation remain the most common issues

Primary care physician Eva Varoqua, MD, answered our questions about how they work and whats on the horizon for these medications

The Pathogenesis of Parkinsons Disease: A Complex Interplay Between Astrocytes, Microglia, and T Lymphocytes

What GLP-1 medications for weight loss are there